Clinical trial
A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.
NCT00506051 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2005
- Completion date
- October 31, 2011
- Enrollment
- 21 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, lung cancer, non-small cell lung